Phaseline

Companies › Seismic Therapeutic AU

Seismic Therapeutic AU: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Other, Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
S-4321
IRAK4 inhibitor (innate immune modulator)
–Phase 1Healthy Volunteer; Autoimmune DiseasesSep 2027
S-1117–Phase 1Healthy Volunteer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06828393S-1117Phase 1Healthy VolunteerOtherMar 2026
NCT06877611S-4321Phase 1Healthy VolunteerOtherApr 2026
NCT07455578S-4321Phase 1Autoimmune DiseasesImmunologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.